HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2008
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23448
Acceso en línea:
https://doi.org/10.1016/j.vaccine.2008.09.073
https://repository.urosario.edu.co/handle/10336/23448
Palabra clave:
Placebo
Silgard
Unclassified drug
Virus antibody
Wart virus vaccine
Adolescent
Adult
Antibody production
Antibody response
Article
Cancer immunization
Cancer prevention
Clinical trial
Controlled clinical trial
Controlled study
Double blind procedure
Drug efficacy
Female
Human
Infection prevention
Major clinical study
Phase 3 clinical trial
Priority journal
Randomized controlled trial
Uterine cervix carcinoma in situ
Wart virus
Adolescent
Condylomata acuminata
Female
Follow-up studies
Human papillomavirus 11
Human papillomavirus 16
Human papillomavirus 18
Human papillomavirus 6
Humans
Immunization schedule
Papillomavirus infections
Papillomavirus vaccines
Reverse transcriptase polymerase chain reaction
Vagina
Vaginal smears
Vulva
Young adult
Human papillomavirus
Humoral immunity
Immune memory
viral
Antibodies
Rights
License
Abierto (Texto Completo)
id EDOCUR2_0da5ad858134d2d07fceda8bf0c9b85a
oai_identifier_str oai:repository.urosario.edu.co:10336/23448
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
dc.title.spa.fl_str_mv HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
title HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
spellingShingle HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
Placebo
Silgard
Unclassified drug
Virus antibody
Wart virus vaccine
Adolescent
Adult
Antibody production
Antibody response
Article
Cancer immunization
Cancer prevention
Clinical trial
Controlled clinical trial
Controlled study
Double blind procedure
Drug efficacy
Female
Human
Infection prevention
Major clinical study
Phase 3 clinical trial
Priority journal
Randomized controlled trial
Uterine cervix carcinoma in situ
Wart virus
Adolescent
Condylomata acuminata
Female
Follow-up studies
Human papillomavirus 11
Human papillomavirus 16
Human papillomavirus 18
Human papillomavirus 6
Humans
Immunization schedule
Papillomavirus infections
Papillomavirus vaccines
Reverse transcriptase polymerase chain reaction
Vagina
Vaginal smears
Vulva
Young adult
Human papillomavirus
Humoral immunity
Immune memory
viral
Antibodies
title_short HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
title_full HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
title_fullStr HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
title_full_unstemmed HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
title_sort HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
dc.subject.keyword.spa.fl_str_mv Placebo
Silgard
Unclassified drug
Virus antibody
Wart virus vaccine
Adolescent
Adult
Antibody production
Antibody response
Article
Cancer immunization
Cancer prevention
Clinical trial
Controlled clinical trial
Controlled study
Double blind procedure
Drug efficacy
Female
Human
Infection prevention
Major clinical study
Phase 3 clinical trial
Priority journal
Randomized controlled trial
Uterine cervix carcinoma in situ
Wart virus
Adolescent
Condylomata acuminata
Female
Follow-up studies
Human papillomavirus 11
Human papillomavirus 16
Human papillomavirus 18
Human papillomavirus 6
Humans
Immunization schedule
Papillomavirus infections
Papillomavirus vaccines
Reverse transcriptase polymerase chain reaction
Vagina
Vaginal smears
Vulva
Young adult
Human papillomavirus
Humoral immunity
Immune memory
topic Placebo
Silgard
Unclassified drug
Virus antibody
Wart virus vaccine
Adolescent
Adult
Antibody production
Antibody response
Article
Cancer immunization
Cancer prevention
Clinical trial
Controlled clinical trial
Controlled study
Double blind procedure
Drug efficacy
Female
Human
Infection prevention
Major clinical study
Phase 3 clinical trial
Priority journal
Randomized controlled trial
Uterine cervix carcinoma in situ
Wart virus
Adolescent
Condylomata acuminata
Female
Follow-up studies
Human papillomavirus 11
Human papillomavirus 16
Human papillomavirus 18
Human papillomavirus 6
Humans
Immunization schedule
Papillomavirus infections
Papillomavirus vaccines
Reverse transcriptase polymerase chain reaction
Vagina
Vaginal smears
Vulva
Young adult
Human papillomavirus
Humoral immunity
Immune memory
viral
Antibodies
dc.subject.keyword.eng.fl_str_mv viral
Antibodies
description The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. © 2008 Elsevier Ltd. All rights reserved.
publishDate 2008
dc.date.created.spa.fl_str_mv 2008
dc.date.accessioned.none.fl_str_mv 2020-05-26T00:02:06Z
dc.date.available.none.fl_str_mv 2020-05-26T00:02:06Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.vaccine.2008.09.073
dc.identifier.issn.none.fl_str_mv 0264410X
13588745
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/23448
url https://doi.org/10.1016/j.vaccine.2008.09.073
https://repository.urosario.edu.co/handle/10336/23448
identifier_str_mv 0264410X
13588745
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 6851
dc.relation.citationIssue.none.fl_str_mv No. 52
dc.relation.citationStartPage.none.fl_str_mv 6844
dc.relation.citationTitle.none.fl_str_mv Vaccine
dc.relation.citationVolume.none.fl_str_mv Vol. 26
dc.relation.ispartof.spa.fl_str_mv Vaccine, ISSN:0264410X, 13588745, Vol.26, No.52 (2008); pp. 6844-6851
dc.relation.uri.spa.fl_str_mv https://www.scopus.com/inward/record.uri?eid=2-s2.0-56949087305&doi=10.1016%2fj.vaccine.2008.09.073&partnerID=40&md5=d26d764753441b12cfbb7a520688ce75
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1828160550667812864
spelling a75a5428-1aaa-4075-a93f-98e319385bad-1ecccb0c4-cb95-4925-af5a-1ec964a2d76a-131b00978-d6b8-47c4-8a44-de2e315d2c8f-1aee4222e-774f-4684-9beb-4069b3db2716-1a016ed9a-4c40-4d3d-a538-a083f496ecc3-191d013f4-fece-4425-9068-a40f15ef934e-11dfc1d2b-911c-4aca-8dcd-77db5e092a42-1ac25aff2-3f7c-4ce9-98ef-b530755dbbc5-15094f39e-ccc9-48de-bede-b0481f534e8b-16b1eabf1-f5a4-4c7d-8d19-e055c1e32beb-1f10b7b3e-387f-4a90-94d3-de6c2ab8febf-1c59fe302-1d33-46e7-9505-6ccce05f4e7d-17f622cbd-6336-4a57-86d9-2da5efa57292-102fc9572-3dd6-40b2-80e7-bce5fbdd1eb0-1a65a15e3-6329-4786-a619-3a597770eff2-13c777468-016c-4688-b158-d4665174c3ee-158e46619-3a93-4b53-b4be-ac14b26bd165-13222d7b8-c070-4fc3-ae6c-6669826baf18-1cc491ce4-376e-4bd5-8962-5c82898472e1-1336e5d2c-2912-493d-a9fd-5d88fc6c566b-15889396a-284a-4576-a52c-e0d1f0c0f17b-162246fe4-4b85-4ccf-a7d3-7dc9ccaefe1c-140666f10-445b-4ccd-bae5-5381ba94f10d-15d07d84d-c1e8-4a2f-aed7-3bcaa13e0f79-182d160ec-619b-4e48-881b-b44d9e76fc63-1dcc194ad-98c2-4d71-8f0f-af895f661918-18a12e6d3-0263-47e3-8659-6e430f156601-1195cb5d0-9377-4dd6-b8fb-fdb31f36685a-19ea37233-65a2-464d-9e15-119e19583d07-1ce178588-a76d-43dd-aa4b-168721304f1b-1452b9c69-e9c0-4a80-abf3-d1bf4605f687-115d08f78-346e-493e-a24d-b07c151cb9fe-16bac68bd-ae22-45ec-b319-37d35ad26368-11474d0c8-dff7-4636-ba59-d342e91947ce-1dc4e5bce-11ba-4c28-8b4a-7aefe50942e4-123aa560d-194f-491c-a2bd-f00b038fe1f6-1e8151c88-7be0-4a39-bdee-a29f39c971b7-135dcdcbb-f667-458d-966c-e81ed018edd9-12020-05-26T00:02:06Z2020-05-26T00:02:06Z2008The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers. © 2008 Elsevier Ltd. All rights reserved.application/pdfhttps://doi.org/10.1016/j.vaccine.2008.09.0730264410X13588745https://repository.urosario.edu.co/handle/10336/23448eng6851No. 526844VaccineVol. 26Vaccine, ISSN:0264410X, 13588745, Vol.26, No.52 (2008); pp. 6844-6851https://www.scopus.com/inward/record.uri?eid=2-s2.0-56949087305&doi=10.1016%2fj.vaccine.2008.09.073&partnerID=40&md5=d26d764753441b12cfbb7a520688ce75Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURPlaceboSilgardUnclassified drugVirus antibodyWart virus vaccineAdolescentAdultAntibody productionAntibody responseArticleCancer immunizationCancer preventionClinical trialControlled clinical trialControlled studyDouble blind procedureDrug efficacyFemaleHumanInfection preventionMajor clinical studyPhase 3 clinical trialPriority journalRandomized controlled trialUterine cervix carcinoma in situWart virusAdolescentCondylomata acuminataFemaleFollow-up studiesHuman papillomavirus 11Human papillomavirus 16Human papillomavirus 18Human papillomavirus 6HumansImmunization schedulePapillomavirus infectionsPapillomavirus vaccinesReverse transcriptase polymerase chain reactionVaginaVaginal smearsVulvaYoung adultHuman papillomavirusHumoral immunityImmune memoryviralAntibodiesHPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccinearticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Joura, Elmar A.Kjaer, Susanne K.Wheeler, Cosette M.Sigurdsson, KristjánIversen, Ole-ErikHernandez-Avila, MauricioPerez, GonzaloBrown, Darron R.Koutsky, Laura A.Tay, Eng HseonGarcía, PatriciaAult, Kevin A.Garland, Suzanne M.Leodolter, SeppOlsson, Sven-EricTang, Grace W.K.Ferris, Daron G.Paavonen, JormaLehtinen, MattiSteben, MarcBosch, XavierDillner, JoakimKurman, Robert J.Majewski, SlawomirMuñoz, NubiaMyers, Evan R.Villa, Luisa L.Taddeo, Frank J.Roberts, ChristineTadesse, AmhaBryan, JanineLupinacci, Lisa C.Giacoletti, Katherine E.D.Lu, ShuangVuocolo, ScottHesley, Teresa M.Haupt, Richard M.Barr, Eliav10336/23448oai:repository.urosario.edu.co:10336/234482022-05-02 07:37:21.514609https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co